The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

doi:10.19401/j.cnki.1007-3639.2023.11.001

Abstract

Abstract:

Many major research achievements have been made in the past year in the field of gynecologic oncology (cervical cancer, ovarian cancer and endometrial cancer), including surgical treatment, local advanced treatment mode and exploration of new treatments for recurrence and metastasis. Especially the research of emerging treatment methods such as immunotherapy, targeted therapy and antibody-drug conjugate therapy has opened a new era of treatment and brought more hopes for treatment to patients. This paper summarizes the major advances in surgical treatment, radiotherapy, chemotherapy and novel targeted immunotherapy for gynecologic oncology at 2023 Annual Meeting of European Society for Medical Oncology (ESMO), in order to better guide the individualized precision treatment.

Key words: Cervical cancer, Ovarian cancer, Endometrial cancer, Immunotherapy, Targeted therapy, Antibody-drug conjugate

CLC Number:

R737.3

XIA Lingfang, ZHU Jun, WU Xiaohua. The latest progress and prospect of gynecological tumor treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 969-980.

References 35

[1]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
	ZHENG R S, ZHANG S W, SUN K X, et al. Cancer statistics in China, 2016[J]. Chin J Oncol, 2023, 45(3): 212-220.
[2]	MCCORMACK M, GALLARDO RINCÓN D, EMINOWICZ G, et al. A randomised phase Ⅲ trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial[J]. Ann Oncol, 2023, 34: S1276.
[3]	MILESHKIN L R, MOORE K N, BARNES E H, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2023, 24(5): 468-482. doi: 10.1016/S1470-2045(23)00147-X pmid: 37080223
[4]	LORUSSO D, XIANG Y, HASEGAWA K, et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase Ⅲ ENGOT-cx11/GOG-3047/KEYNOTE-A18 study[J]. Ann Oncol, 2023, 34: S1279-S1280. doi: 10.1016/j.annonc.2023.10.032
[5]	MAYADEV J, NUNES A T, LI M, et al. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase Ⅲ, randomized, double-blind, multicenter study[J]. Int J Gynecol Cancer, 2020, 30(7): 1065-1070. doi: 10.1136/ijgc-2019-001135
[6]	LEATH C A, DENG W, MELL L K, et al. Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase Ⅲ randomized trial[J]. J Clin Oncol, 2023, 41(16_suppl): 5502. doi: 10.1200/JCO.2023.41.16_suppl.5502
[7]	COLOMBO N, DUBOT C, LORUSSO D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. doi: 10.1056/NEJMoa2112435
[8]	MONK B J, COLOMBO N, TEWARI K S, et al. First-line pembrolizumab+chemotherapy versus placebo+chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826[J]. J Clin Oncol, 2023: JCO2300914.
[9]	LIU N, YANG Z, TANG D, et al. Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase Ⅱ study[J]. Ann Oncol, 2023, 34: S509.
[10]	GAO X, XU N, LI Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial[J]. Lancet Oncol, 2023, 24(10): 1134-1146. doi: 10.1016/S1470-2045(23)00411-4 pmid: 37797632
[11]	WU X, XIA L, ZHANG K, et al. Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer[J]. Ann Oncol, 2023, 34: S1284-S1285.
[12]	LEE J Y, WU L, BOONYAPIPAT S, et al. AdvanTIG-202: phaseⅡ randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)[J]. Ann Oncol, 2023, 34: S509-S510.
[13]	VERGOTE I B, GONZALEZ MARTIN A, FUJIWARA K, et al. InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase Ⅲ study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer[J]. Ann Oncol, 2023, 34: S1276-S1277.
[14]	XIA B, JIANG W, CHEN J, et al. Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase Ⅱ clinical study[J]. Ann Oncol, 2023, 34: S520.
[15]	National Comprehensive Cancer Network. NCCN Guidelines for treatment of ovarian cancer, 2023 V2[EB/OL]. [2023-11-15]. https://www.nccn.org.
[16]	中国抗癌协会妇科肿瘤专业委员会, 中国抗癌协会肿瘤多学科诊疗(MDT)专业委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 妇科恶性肿瘤多学科诊疗中国专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(8): 747-756. doi: 10.19401/j.cnki.1007-3639.2022.08.010
	The Society of Gynecological Cancer of China Anti-Cancer Association, Multidisciplinary Diagnosis and Treatment (MDT) Committee of China Anti-Cancer Association, Multidisciplinary Cancer Diagnosis and Treatment Committee of Chinese Medical Doctor Association. Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition)[J]. Chin Oncol, 2022, 32(8): 747-756. doi: 10.19401/j.cnki.1007-3639.2022.08.010
[17]	WU X H, LIU J H, WANG X B, et al. Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): a randomized, double-blind, placebo-controlled, phase 3 trial[C]. Late Breaking Abstracts. BMJ Publishing Group Ltd, 2023.
[18]	FLOOR B, TIRZA A C B, JESSICA P, et al. Real-world time to treatment discontinuation of first-line maintenance niraparib monotherapy in epithelial ovarian cancer: CHAR1ZMA study[C]. 2023 ESMO, Abs 789P.
[19]	KURTZ J E, PUJADE-LAURAINE E, OAKNIN A, et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase Ⅲ ATALANTE/ENGOT-ov29 trial[J]. J Clin Oncol, 2023, 41(30): 4768-4778. doi: 10.1200/JCO.23.00529
[20]	PUJADE-LAURAINE E, FUJIWARA K, LEDERMANN J A, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study[J]. Lancet Oncol, 2021, 22(7): 1034-1046. doi: 10.1016/S1470-2045(21)00216-3
[21]	HARTER P, TRILLSCH F, OKAMOTO A, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase Ⅲ DUO-O trial[J]. J Clin Oncol, 2023, 41(17_suppl): LBA5506. doi: 10.1200/JCO.2023.41.17_suppl.LBA5506
[22]	GONZALEZ MARTIN A, RUBIO PEREZ M J, HEITZ F, et al. Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase Ⅲ trial[J]. Ann Oncol, 2023, 34: S1278-S1279. doi: 10.1016/j.annonc.2023.10.031
[23]	LIU J F, BRADY M, MATULONIS U A, et al. Overall survival (OS) outcomes from NRG-GY004, a phase Ⅲ study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)[J]. Ann Oncol, 2023, 34: S1285. doi: 10.1016/j.annonc.2023.10.039
[24]	LIU J F, BARRY W T, BIRRER M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1207-1214. doi: 10.1016/S1470-2045(14)70391-2 pmid: 25218906
[25]	WU X, LIU J, WANG L, et al. SABRINA study: a phase Ⅱ study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)[J]. Ann Oncol, 2023, 34: S521.
[26]	LEE J M. Randomized phase Ⅱ trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)[J]. Ann Oncol, 2023, 34: S511.
[27]	MOORE K N, PHILIPOVSKIY A, HARANO K, et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase Ⅰ study[J]. Ann Oncol, 2023, 34: S510. doi: 10.1016/j.annonc.2023.09.1924
[28]	HOWLETT S, BERNER A M, CONNOLLY K, et al. Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients[J]. Ann Oncol, 2023, 34: S535.
[29]	DE BRUYN M, EERKENS A L, BRUMMEL K, et al. Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer[J]. Ann Oncol, 2023, 34: S508-S509.
[30]	MIRZA M R, SHARMA S, HERRSTEDT J, et al. Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial[J]. Ann Oncol, 2023, 34: S507. doi: 10.1016/j.annonc.2023.09.1919
[31]	ESKANDER R N, SILL M, MILLER A, et al. Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial[J]. Ann Oncol, 2023, 34: S1284.
[32]	NICOLETTA C. Phase Ⅲ double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: ENGOT-en7/MaNGO/AtTEnd study[C]. 2023 ESMO, Abs LBA40.
[33]	WESTIN S N, MOORE K N, CHON H S, et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva±olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase Ⅲ DUO-E/GOG-3041/ENGOT-EN10 trial[J]. Ann Oncol, 2023, 34: S1282-S1283. doi: 10.1016/j.annonc.2023.10.035
[34]	JOLY LOBBEDEZ F, LEARY A, RAY-COQUARD I L, et al. Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase Ⅱb UTOLA trial[J]. Ann Oncol, 2023, 34: S1283-S1284. doi: 10.1016/j.annonc.2023.10.036
[35]	POTHURI B, NAUMANN R W, MARTIN L P, et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase Ⅰ dose expansion[J]. Ann Oncol, 2023, 34: S508.